Amryt Pharma PLC Director/PDMR Shareholding (1189C)
11 April 2017 - 2:21AM
UK Regulatory
TIDMAMYT
RNS Number : 1189C
Amryt Pharma PLC
10 April 2017
10 April 2017
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Director Share Purchase
Amryt, the pharmaceutical company focused on best-in-class
treatments for rare and orphan diseases, announces that it has been
notified that Markus Ziener, Non-Executive Director, has purchased
100,000 ordinary shares of 1p each ("Ordinary Shares") at a price
of 21.5p per Ordinary Share.
Following this transaction, Mr Ziener holds 100,000 Ordinary
Shares, representing 0.05% of the Company's issued share capital
(excluding treasury shares). Mr Ziener is the Executive Managing
Director of Software AG Stiftung, a 20.9% shareholder in Amryt.
Full details as required under the Market Abuse Regulation are
set out below.
Notification of Transactions of Directors / Persons Discharging
Managerial Responsibility and Connected Persons
1 Details of the person discharging managerial
responsibilities / person closely associated
--- --------------------------------------------------------
a) Name Markus Ziener
--- ------------------------- -----------------------------
2 Reason for the notification
--- --------------------------------------------------------
a) Position/status Non-Executive Director
--- ------------------------- -----------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------- -----------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- --------------------------------------------------------
a) Name Amryt Pharma plc
--- ------------------------- -----------------------------
b) LEI 213800BOS8WAJO2BEQ38
--- ------------------------- -----------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- --------------------------------------------------------
a) Description of
the financial Ordinary shares of 1p each
instrument, type in Amryt Pharma plc
of instrument
GB00BDD1LS57
Identification
code
--- ------------------------- -----------------------------
b) Nature of the Purchase of shares
transaction
--- ------------------------- -----------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
21.5p 100,000
--------- ----------
--- ------------------------- -----------------------------
d) Aggregated information
- Aggregated volume
- Price N/A (single transaction)
--- ------------------------- -----------------------------
e) Date of the transaction 30/03/17
--- ------------------------- -----------------------------
f) Place of the transaction London Stock Exchange, AIM
Market (XLON)
--- ------------------------- -----------------------------
Enquiries:
Amryt Pharma plc C/o KTZ Communications
Joe Wiley, CEO
Rory Nealon, CFO/COO
+44 (0) 20
Shore Capital 7408 4090
Nomad and Joint Broker
Bidhi Bhoma, Edward Mansfield
+353 (1) 679
Davy 6363
ESM Adviser and Joint
Broker
John Frain, Anthony Farrell
+44 (0) 20
Stifel 7710 7600
Joint Broker
Jonathan Senior, Ben
Maddison
+44 (0) 20
KTZ Communications 3178 6378
Katie Tzouliadis, Emma
Pearson
About Amryt Pharma plc - see www.amrytpharma.com
Amryt Pharma is a specialty pharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases. The Company is
building a diversified portfolio of commercially attractive,
best-in-class, proprietary new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
The Company recently acquired an exclusive licence to sell
LOJUXTA (lomitapide), across the EU and other territories including
the Middle East, North Africa, Turkey and Israel. LOJUXTA is used
to treat a rare life-threatening disease called Homozygous Familial
Hypercholesterolemia.
Amryt's product, AP101 (Episalvan), received marketing approval
for the treatment of partial-thickness wounds from the European
Commission in January 2016. Amryt intends to develop AP101
(Episalvan) as a new treatment for Epidermolysis Bullosa ("EB"), a
rare and distressing genetic skin disorder affecting young children
for which there is currently no treatment. The Company recently
received regulatory clarity from the FDA and the EMA regarding its
Phase 3 study of AP101 (Episalvan) in EB, which has been granted US
and EU orphan drug designation, and the first study site was
initiated at the end of March 2017. The global market opportunity
for EB is estimated to be in excess of EUR 1.3 billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease. AP102 was recently granted orphan designation in
the US in acromegaly by the FDA.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHOKKDDABKDCQD
(END) Dow Jones Newswires
April 10, 2017 12:21 ET (16:21 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024
